NASDAQ:CDIO

Cardio Diagnostics Q3 2025 Earnings Results & Report

Cardio Diagnostics logo
$1.60 -0.05 (-3.03%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.60 -0.01 (-0.31%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardio Diagnostics beat analyst earnings expectations but missed on revenue in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.98 versus the -$1.80 consensus estimate, while revenue of $3 thousand fell short of the $150 thousand estimate by $147 thousand.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens

Cardio Diagnostics EPS Results

Actual EPS
-$0.98
Consensus EPS
-$1.80
Beat/Miss
Beat by +$0.82
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

Cardio Diagnostics Revenue Results

Actual Revenue
$3 thousand
Expected Revenue
$150 thousand
Beat/Miss
Missed by -$147.00 thousand
YoY Revenue Growth
N/A

Conference Call Resources

Cardio Diagnostics Q3 2025 Earnings FAQ

Cardio Diagnostics (NASDAQ:CDIO) reported earnings of -$0.98 per share for Q3 2025, beating the consensus estimate of -$1.80. The report was announced on Wednesday, November 12, 2025.

Cardio Diagnostics reported revenue of $3 thousand for Q3 2025, against a consensus estimate of $150 thousand.

Cardio Diagnostics Earnings Headlines

The warning signs most investors see too late
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) develops blood-based tests and technology for cardiovascular disease assessment. Its platform combines genetic and epigenetic information with artificial intelligence to support more personalized evaluation of heart disease.

The company’s offerings include Epi+Gen CHD, designed to assess a person’s risk of coronary heart disease, and PrecisionCHD, a test intended to help identify coronary heart disease in people being evaluated for the condition. The tests are designed to complement clinical assessment and are not a substitute for care from a health professional.

Founded in 2017 and based in Chicago, Illinois, Cardio Diagnostics was co-founded by Meesha Dogan, who serves as its chief executive officer. The company focuses primarily on making its testing services available in the United States.

View Cardio Diagnostics Profile